Amylin Pharmaceuticals signs obesity drug deal with Takeda potentially worth over $1 billionNovember 2nd, 2009 more images
more images
Amylin signs obesity drug deal with Takeda
NEW YORK — Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co.
Amylin Pharmaceuticals signs weight-loss drug deal with Takeda potentially worth over $1BNovember 2nd, 2009 more images
more images
Amylin signs weight-loss drug deal with Takeda
NEW YORK — Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co.
AstraZeneca posts 22 percent rise in third quarter profits amid demand for swine flu vaccineOctober 29th, 2009 more images
more images
AstraZeneca 3Q earns up 22 percent
LONDON — Pharmaceutical company AstraZeneca PLC posted a 22 percent rise in third quarter net profit on Thursday, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States. The expectation of further profits expected from its Novel Influenza A vaccine for the H1N1 led AstraZeneca to lift its full-year earnings forecast.
How fish oils help fight arthritisOctober 29th, 2009 LONDON - Fish oils are known for their beneficial health effects, but how and why they produce anti-inflammatory effects remains uncertain. Now, British researchers claim to have uncovered a mechanism that explains why taking fish oils can help with conditions like rheumatoid arthritis.n the new study, the research team showed how the body converts an ingredient found in fish oils into another chemical called Resolvin D2 and how this chemical reduces the inflammation that leads to a variety of diseases.
Drugmaker Bristol-Myers posts higher 3Q sales, but lower profit due to $2B gain a year agoOctober 22nd, 2009 Bristol-Myers posts higher 3Q sales, lower profitTRENTON, N.J. — Drugmaker Bristol-Myers Squibb Co.
Bristol-Myers faces growing competition for key drugs as it reports 3Q resultsOctober 21st, 2009 Earnings Preview: Bristol-Myers 3Q earnings reportNEW YORK — Bristol-Myers Squibb Co., the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning.
Medco says it will run clinical trial to compare blood thinners Plavix and EffientOctober 19th, 2009 Medco plans to compare Plavix, Effient in studyNEW YORK — Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with the newer Effient.
FDA rejects expanded use of rheumatoid arthritis drug RituxanOctober 17th, 2009 FDA nixes wider use of rheumatoid arthritis drugThe Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
Onyx will acquire Proteolix and its blood cancer drug candidate in deal worth up to $851MOctober 12th, 2009 Onyx Pharma will pay up to $851M for ProteolixNEW YORK — Onyx Pharmaceuticals Inc. said Monday it will buy cancer drug developer Proteolix Inc.
FDA panel favors expanded approval for Pfizer HIV drug as an initial treatmentOctober 8th, 2009 FDA panel backs expanded use of Pfizer HIV drugADELPHI, Md. — Federal health advisers said Thursday that Pfizer's HIV drug Selzentry should be approved for use by patients who have not already taken other drugs to combat the virus.
Saliva-based genetic test helps doctors identify patients who would not respond to PlavixOctober 7th, 2009 Test detects patients who don't respond to PlavixWASHINGTON — "Just spit." With those simple instructions, health care providers in California are hoping to expand the use of genetic testing to make sure patients get the right medication. Scripps Health hospital system has begun using a saliva-based genetic test to detect whether patients will respond to Plavix, a widely used blood thinner that usually prevents clots.
FDA says Pfizer's pill Selzentry appears safe for broader use against HIVOctober 6th, 2009 FDA sees no safety issues with Pfizer HIV drugWASHINGTON — The Food and Drug Administration said Tuesday an HIV drug from Pfizer appears safe for expanded use in patients who have not already taken other drugs to combat the virus. However, the FDA said Pfizer studies paint a mixed picture of its drug's effectiveness.
NxStage Medical signs 3-year deal to supply Reliant Renal Care with dialysis productsSeptember 14th, 2009 NxStage Medical signs 3-year supply dealLAWRENCE, Mass. — Medical device maker NxStage Medical Inc.
ZymoGenetics says Atacicept did not meet goals for advancing directly to late-stage testingSeptember 10th, 2009 ZymoGenetics says RA drug misses advancement goalsSEATTLE — ZymoGenetics Inc. said Thursday that its drug candidate Atacicept did not meet goals that would have automatically advanced it to late-stage clinical testing as a treatment for rheumatoid arthritis.
Gene behind gum disease, osteoporosis, arthritis identifiedAugust 31st, 2009 WASHINGTON - An international team of researchers have identified a gene that is common in the development of gum disease, rheumatoid arthritis, and osteoporosis. Experts at Hospital for Special Surgery say that their findings about the gene, called interferon regulator factor-8 (IRF-8), may lead to new treatments in future.
